LOXO-195
E564270
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
All labels observed (2)
How this entity was disambiguated
This entity first appeared as the object of triple T6003724 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: LOXO-195 Context triple: [Loxo Oncology, developedDrug, LOXO-195]
-
A.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
B.
LOXO
LOXO was the stock ticker symbol for Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies before its acquisition.
-
C.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: LOXO-195 Target entity description: LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
A.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
B.
LOXO
LOXO was the stock ticker symbol for Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies before its acquisition.
-
C.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
Statements (42)
| Predicate | Object |
|---|---|
| instanceOf |
TRK inhibitor
ⓘ
investigational drug ⓘ small molecule drug ⓘ targeted cancer therapy ⓘ |
| administeredBy | oral route ⓘ |
| belongsToClass |
protein kinase inhibitors
ⓘ
tyrosine kinase inhibitors ⓘ |
| bindingTarget |
mutant TRK proteins
ⓘ
wild-type TRK proteins ⓘ |
| designedFor | NTRK fusion–positive cancers ⓘ |
| designedToOvercome |
acquired resistance to first-generation TRK inhibitors
ⓘ
gatekeeper mutations in NTRK genes ⓘ solvent-front mutations in NTRK genes ⓘ |
| developedAs | second-generation TRK inhibitor ⓘ |
| developedBy | Loxo Oncology NERFINISHED ⓘ |
| developedInCollaborationWith | Bayer NERFINISHED ⓘ |
| hasAlternativeName |
BAY 2731954
NERFINISHED
ⓘ
selitrectinib NERFINISHED ⓘ |
| hasBiomarker | NTRK gene fusion ⓘ |
| hasDesignGoal |
maintain potency against TRK resistance mutations
ⓘ
minimize off-target kinase inhibition ⓘ |
| hasEffect | inhibition of TRK signaling pathways ⓘ |
| hasIndication |
NTRK fusion–positive solid tumors progressing on larotrectinib
ⓘ
cancers resistant to earlier TRK-targeted therapies ⓘ |
| hasProperty |
highly selective for TRK over other kinases
ⓘ
next-generation TRK inhibitor ⓘ |
| hasResistanceContext | acquired resistance to TRK inhibition ⓘ |
| hasTherapeuticArea | oncology ⓘ |
| investigatedIn | clinical trials ⓘ |
| mechanismOfAction | selective inhibition of TRK kinases ⓘ |
| molecularTargetType | receptor tyrosine kinase ⓘ |
| phaseOfDevelopment | clinical development ⓘ |
| predecessorDrug | larotrectinib NERFINISHED ⓘ |
| targets |
NTRK1
NERFINISHED
ⓘ
NTRK2 NERFINISHED ⓘ NTRK3 NERFINISHED ⓘ tropomyosin receptor kinase A NERFINISHED ⓘ tropomyosin receptor kinase B ⓘ tropomyosin receptor kinase C ⓘ |
| therapeuticModality | small-molecule kinase inhibitor ⓘ |
| usedFor | precision oncology treatment based on NTRK alterations ⓘ |
| usedIn | treatment of solid tumors with NTRK gene fusions ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: LOXO-195 Description of subject: LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology
subject surface form:
Loxo Oncology
this entity surface form:
LOXO-101